J. Goldman & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Goldman & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.47M	Buy	+10,000	New	+$4.66M	0.13%	199
2025 Q1	–	Sell	-6,000	Closed	-$2.42M	–	658
2024 Q4	$2.42M	Buy	+6,000	New	+$2.78M	0.06%	262
2024 Q1	–	Sell	-8,200	Closed	-$3.34M	–	527
2023 Q4	$3.34M	Buy	+8,200	New	+$3.03M	0.14%	152
2023 Q1	–	Sell	-55,000	Closed	-$15.9M	–	492
2022 Q4	$15.9M	Buy	+55,000	New	+$16.8M	0.78%	35
2022 Q1	–	Sell	-7,500	Closed	-$1.65M	–	454
2021 Q4	$1.65M	Buy	+7,500	New	+$1.46M	0.09%	221
2021 Q2	–	Sell	-33,700	Closed	-$7.24M	–	526
2021 Q1	$7.24M	Buy	+33,700	New	+$7.4M	0.23%	112

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

J. Goldman & Co's VRTX Position: Q3 2025 in Review

J. Goldman & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,045 shares — an estimated $465K sold.

J. Goldman & Co first reported a position in VRTX in Q2 2017 and held it in 8 quarters. The position peaked at $8.71M in Q4 2022. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

J. Goldman & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J. Goldman & Co sold 1,045 Vertex Pharmaceuticals shares in Q3 2025, an estimated $465K.
J. Goldman & Co first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 8 quarters.
J. Goldman & Co's Vertex Pharmaceuticals position peaked at $8.71M in Q4 2022.
1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.